Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.39 |
| ▸ | ITGAV | P06756 | 1/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.38 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.38 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27508499 | 0.82 | CFTR (0.44) | CFTRSLC6A2SLC6A4SLC6A3GOPC | |
| SCHEMBL7045556 | 0.82 | SMN1; SMN2 (0.47) | CFTRSLC6A2SLC6A4SLC6A3GOPC | |
| SCHEMBL3534814 | 0.77 | LMNA (0.46) | LMNA | |
| SCHEMBL658876 | 0.75 | CFTR (0.57) | CFTRSLC6A2SLC6A4SLC6A3GOPC | |
| SCHEMBL12154822 | 0.75 | CFTR (0.52) | CFTRSLC6A2SLC6A4SLC6A3GOPC | |
| SCHEMBL1245510 | 0.73 | NPC1 (0.53) | CFTRSLC6A2SLC6A4SLC6A3GOPC | |
| SCHEMBL22113733 | 0.73 | NPC1 (0.53) | CFTRSLC6A2SLC6A4SLC6A3GOPC | |
| SCHEMBL14233502 | 0.73 | NPC1 (0.53) | CFTRSLC6A2SLC6A4SLC6A3GOPC | |
| SCHEMBL19606204 | 0.72 | SMN1; SMN2 (0.42) | CFTRSLC6A2SLC6A4SLC6A3GOPC | |
| SCHEMBL21162240 | 0.72 | SMN1; SMN2 (0.39) | CFTRSLC6A2SLC6A4SLC6A3GOPC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230123589-A1 | MOLECULAR MOBILITY ENHANCER OR MOLECULAR DRYING ENHANCER | TEKDRY INTERNATIONAL, INC. | 2023-04-20 | — | — | US | disclosed |
| EP-4097386-A1 | MOLECULAR MOBILITY ENHANCER OR MOLECULAR DRYING ENHANCER | TekDry International, Inc. (US) | 2022-12-07 | — | — | EP | disclosed |
| WO-2021154959-A1 | MOLECULAR MOBILITY ENHANCER OR MOLECULAR DRYING ENHANCER | TEKDRY INTERNATIONAL, INC. (US) | 2021-08-05 | — | — | WO | disclosed |
| US-7714099-B2 | Luminescent compositions and their uses | HITACHI CHEMICAL CO., LTD. (JP) | 2010-05-11 | — | — | US | disclosed |
| US-20060083945-A1 | New luminescent compositions and their uses | HITACHI CHEMICAL CO. LTD. (JP) | 2006-04-20 | — | — | US | disclosed |
| WO-2006041221-A1 | NEW LUMINESCENT COMPOSITIONS AND THEIR USES | HITACHI CHEMICAL CO., LTD. (JP) | 2006-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060083945-A1 | New luminescent compositions and their uses | OCIAD1, NLRP3, OCIAD2 | CFTR 3764/4885SLC6A2 3980/4885SLC6A4 2228/4885 |
| US-20230123589-A1 | MOLECULAR MOBILITY ENHANCER OR MOLECULAR DRYING ENHANCER | SNRPE, MTREX, MMP20 | CFTR 180/4885SLC6A2 4298/4885SLC6A4 3331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.